@Nefrontera

MD, PhD| Nephrologist| Hereditary Kidney Disease Fellow-UHN| IMS UofTo| ADPKD| AI in Med| @GlomCon educator| @GlomConILA| 🇨🇴🇪🇸🇨🇦🌐

 Toronto, Ontario
Joined April 2019
  • Tweets1.4K
  • Following1K
  • Followers1.6K
371Media
🧬Really nice talk by Dr. Jan Halbritter about genetic testing in CKDx. Let's not forget the blind spots of genetic testing! He presented a tool for genotyping MUC1 VNTR from short-read data. pmc.ncbi.nlm.nih.gov/article… medrxiv.org/content/10.64898… – at Denver, CO
1
1
119
Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis: Sibeprenlimab treatment led to a 97.1% risk reduction (95% CI, 78.6–99.6). nejm.org/doi/full/10.1056/NE… – at Denver, CO
1
5
360
Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis #KidneyWk nejm.org/doi/full/10.1056/NE… – at Denver, CO

Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis | NEJM

Atacicept resulted in a significantly greater reduction in the urinary protein-to-creatinine ratio than placebo in a previously published analysis of this trial, ORIGIN 3. Final prespecified effica...

nejm.org
1
5
336
Great talk by Dr. @fouadchebib at #kidneyweek2026 on ADPKD Diagnostic criteria, risk stratification and disease progression! – at Denver, CO
12
370
🩺 Join us for the Toronto PKD Scientific Day on November 7, 2026! An opportunity to explore advances in polycystic kidney disease research and clinical care. In-person or virtual! 📄 Program & registration: wombat-d6770h.my.canva.site/… #ADPKD #PKD #Nephrology #ENDPKD – at Toronto, Ontario
2
1
8
852
Sol Carriazo, Neph. retweeted
GlomCon Ibero-LatinoAmérica@GlomConILAJul 30
🚨No te pierdas este sábado el seminario: ☞ Biopsia renal en el paciente oncológico: expectativas, hallazgos y sorpresas🔬 🗓️ 1/Agosto/26 🗣️ Dra. Verónica Remache 🇪🇨 🗣️ Dr. Washington Osorio 🇪🇨 🕘 9 am CDMX Zoom ID: 863 6358 3637 Pass: 343 190 #GlomConAmor #GlomConILA
1
13
1
28
2,298
Iniciamos en media hora 👇🏽
GlomCon Ibero-LatinoAmérica@GlomConILAJul 16
📢 Este Sábado 18 de Julio!! Seminario de la serie de Genética de GlomCon ILA 🧬 ☞ Amiloidosis renal Hereditaria🧬 🗣️: Dra. Laura Castañeda @casta_ju 🇪🇸 🗓️18/Jul/26 🕘9 am🇲🇽, 10 am🇨🇴, 17 h🇪🇸 Zoom ID: 863 6358 3637 Pass: 343 190
1
331
📢 Este sábado 18 de Julio en @GlomConILA, la Dra. @casta_ju de la Clínica Universitaria de Navarra, nos hablará de Amiloidosis renal hereditaria🧬 🇲🇽 9 a.m 🇪🇸 5 p.m No te lo puedes perder! 👇🏽
GlomCon Ibero-LatinoAmérica@GlomConILAJul 16
📢 Este Sábado 18 de Julio!! Seminario de la serie de Genética de GlomCon ILA 🧬 ☞ Amiloidosis renal Hereditaria🧬 🗣️: Dra. Laura Castañeda @casta_ju 🇪🇸 🗓️18/Jul/26 🕘9 am🇲🇽, 10 am🇨🇴, 17 h🇪🇸 Zoom ID: 863 6358 3637 Pass: 343 190
3
4
409
Sol Carriazo, Neph. retweeted
GlomCon Ibero-LatinoAmérica@GlomConILAJul 1
‼️🚨
2
6
732
1er Máster de Enfermedades Renales Hereditarias en Español!
Mónica Furlano MD, PhD@m_furlanoJun 19
🧬1º Máster en Enfermedades Renales Hereditarias en español 🧬 #GTERH 🗓️Inicio 14/09/2026 al 06/2027 🕒 Inscripciones hasta 16/08/2026 📚Matriculación del 17/08 al 14/09 🎓Título Universitario @uvic_ucc 🌟Reserva tu plaza 👇🏻 ineurocampus.com/master/193/……
1
5
1,625
Sol Carriazo, Neph. retweeted
GlomCon Ibero-LatinoAmérica@GlomConILAJun 16
🚨No te pierdas este sábado el seminario: ☞ Diagnóstico etiológico a partir de un patrón de lesión glomerular🔬 🗓️ 20/junio/26 🗣️ Dr. Rodolfo Guzmán 🇨🇷 🗣️ Dr. Iván Rodríguez 🇲🇽 @goldenglom 🕘 9 am CDMX Zoom ID: 863 6358 3637 Pass: 343 190 #GlomConAmor #GlomConILA
6
2
18
1,455
Today we had an outstanding talk about clinical trials in ADPKD by Dr. @fouadchebib from Mayo Clinic Florida at @GlomCon PKD-MDP. -Consideration for Tolvaptan initiation and referral for possible clinical trials. -Key Milestones in ADPKD and clinical trials
4
13
1,128
Sol Carriazo, Neph. retweeted
Kenar Jhaveri
@kdjhaveriJun 4
Another win for IgAN thelancet.com/journals/lance… @TheLancet Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised,...

Atrasentan reduced proteinuria and preserved kidney function after 2·5 years. This effect was present with or without concomitant SGLT2 inhibitor use. Atrasentan was well tolerated.

thelancet.com
7
18
920
Obinutuzumab vs Tacrolimus in Primary Membranous Nephropathy
NEJM
@NEJMJun 5
Presented at #ERA26: In this 104-week trial involving patients with primary membranous nephropathy, the type II anti-CD20 antibody obinutuzumab was superior to the calcineurin inhibitor tacrolimus in inducing complete remission. Full phase 3 MAJESTY trial results: nej.md/4dZsVPD @ERAkidney
A line graph from an article published in the New England Journal of Medicine compares obinutuzumab and tacrolimus in treating primary membranous nephropathy over 104 weeks. The y-axis represents the percentage of patients relapse‑free, while the x-axis represents weeks. The graph shows two lines, one for obinutuzumab and another for tacrolimus. The image mentions the European Renal Association Congress at the top.

ALT A line graph from an article published in the New England Journal of Medicine compares obinutuzumab and tacrolimus in treating primary membranous nephropathy over 104 weeks. The y-axis represents the percentage of patients relapse‑free, while the x-axis represents weeks. The graph shows two lines, one for obinutuzumab and another for tacrolimus. The image mentions the European Renal Association Congress at the top.

2
10
724
Finerenone in adults with CKD without diabetes
NEJM
@NEJMJun 4
Presented at #ERA26: In adults without diabetes who had chronic kidney disease, the nonsteroidal mineralocorticoid receptor antagonist finerenone led to a slower decrease in the estimate glomerular filtration rate than placebo over 32 months. Full phase 3 FIND-CKD trial results: nej.md/4wWOFV4 @ERAkidney
Graph comparing mean eGFR slopes between finerenone and placebo groups. The chart has three sections: Total, Baseline to Month 3, and Month 3 to End of Treatment. Numerical values are provided above the bars, showing treatment differences with confidence intervals.

ALT Graph comparing mean eGFR slopes between finerenone and placebo groups. The chart has three sections: Total, Baseline to Month 3, and Month 3 to End of Treatment. Numerical values are provided above the bars, showing treatment differences with confidence intervals.

1
3
22
5,224
Sol Carriazo, Neph. retweeted
GlomCon Ibero-LatinoAmérica@GlomConILAJun 3
🚨No te pierdas este sábado el seminario: ☞ El rol de la microscopía electrónica en el diagnóstico de las glomerulopatías 🔬 🗓️ 6/junio/26 🗣️ Dra. Fernanda Toniolo 🇦🇷 🕘 9 am CDMX Zoom ID: 863 6358 3637 Pass: 343 190 #GlomConAmor #GlomConILA
9
1
16
1,200
Sol Carriazo, Neph. retweeted
Mónica Furlano MD, PhD@m_furlanoMay 29
🧬#ADPKD is far more than a #KidneyDisease🧬 It may represent a #systemicvasculopathy driven by #polycystin dysfunction and impaired vascular integrity. 🤔Implications: higher suspicion for acute chest/abdominal pain ajkd.org/article/S0272-6386%…

Association of Autosomal Dominant Polycystic Kidney Disease With Incident Aortic Dissection or...

Autosomal dominant polycystic kidney disease (ADPKD) is characterized by a broad range of extrarenal complications, yet epidemiologic data on its association with aortic dissection (AD) or aortic...

ajkd.org
3
16
729
Sol Carriazo, Neph. retweeted
GlomCon Ibero-LatinoAmérica@GlomConILAMay 21
🚨No te pierdas este sábado el seminario: ☞ Síndrome Riñón-Pulmón 🗣️ Dra. Diana Carolina Vargas 🇨🇴 🗓️23/Mayo/26 🕘9 am CDMX Zoom ID: 863 6358 3637 Pass: 343 190 #GlomConAmor #GlomConILA
6
1
15
1,007
Measuring the Impact of tolvaptan-induced polyuria on quality of life in patients with autosomal dominant polycystic kidney disease
Hans-Joachim Anders@hjanders_hansMay 12
Now open access in @NDTsocial Tolvaptan-induced polyuria and QoL in pts with ADPKD 🧐 This new questionnaire captures the physical, mental, and social burden of tolvaptan-induced polyuria, and provides a reliable PROM for clinical care and research ▶️academic.oup.com/ndt/article…
1
5
586
Sol Carriazo, Neph. retweeted
GlomCon Ibero-LatinoAmérica@GlomConILAMay 6
🚨No te pierdas este sábado el seminario: ☞ Lo nuevo de LRA en KDIGO: volumen, fluidos y HRS-AKI 🗓️ 9/Mayo/26 🗣️ Dr. Hector Antonio Navarrete 🇲🇽 🕘 9 am CDMX Zoom ID: 863 6358 3637 Pass: 343 190 #GlomConAmor #GlomConILA
1
4
1
10
1,031
Load more